London-based EvaluatePharma, a source for life science sector analysis, has launched its new clinical trial intelligence service, EP Clinical Trials. By linking EudraCT and ClinicalTrials.gov records, the new service delivers a unique synthesis of clinical trials information.
"Currently 52% (15,900+ trial records) of the EudraCT clinical trial data, originally released in March 2011, has been made public, and we have successfully linked half of this data via NCT-ID reference number to ClinicalTrials.gov records," said Anthony Raeside, head of research at EvaluatePharma. "Our goal is to continue to make the data as meaningful and valuable as possible by indexing, linking, and revealing previously un-recognized synergies between the public clinical trial directories."
By linking the two leading sources of clinical trial records, additional information benefits include: enrollment numbers available for each E.U. country, trials identified for orphan indications, standardized technology for investigational drugs disclosed, standardized pharmaceutical form such as transdermal patch and the ability to identify commercial company trials unique to the EudraCT site.
EP Clinical Trials is updated daily and also provides mapped data such as biopharmaceutical company and product information, peak and historical sales, indication, top level deal information and custom data alerts and commentary and analysis.